Moreover, an animal study determined that intraperitoneal administration of adropin significantly reduces triglycerides, LDL and total cholesterol while also decreasing blood glucose, insulin levels, and homeostastic model assessment for insulin resistance (HOMA-IR) in rats with hyperlipidemia [8]. The gene discussed is INS; the disease is hyperlipidemia.